Summary & Overview
HCPCS C9141: Injection, Recombinant Pegylated Factor VIII (Jivi), per I.U.
HCPCS Level II code C9141 denotes the injection of recombinant, pegylated factor VIII (Jivi) per 1 international unit for replacement therapy in hemophilia A. This code identifies administration of a long-acting antihemophilic factor used to prevent and control bleeding episodes and for perioperative management. Nationally, accurate coding for high-cost biologic factor products affects claims adjudication, patient access to treatment, and payer reimbursement pathways.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents clinically and administratively, typical sites of service for administration, and what to expect in payer coverage considerations. The publication outlines benchmarking topics such as unit-based reporting, billing practices for infused biologics, and common areas that drive prior authorization or medical necessity reviews. It also situates C9141 within the broader clinical context of hemophilia A management, noting its role as a pegylated recombinant factor VIII product designed for extended half-life replacement therapy.
Data not available in the input for common modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service-line specifics; those items are noted as unavailable and addressed in supplementary tables when present.
Billing Code Overview
HCPCS Level II code C9141 represents injection of factor VIII (antihemophilic factor, recombinant), pegylated-aucl (Jivi), measured per 1 international unit (I.U.). This code is used to report administration of a long-acting recombinant factor VIII product for replacement therapy in patients with hemophilia A.
-
Service type: Therapeutic infusion/injection of clotting factor for hemophilia A
-
Typical site of service: Infusion center, hospital outpatient department, or other outpatient clinical setting where intravenous factor replacement is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult male with severe hemophilia A (congenital deficiency of factor VIII) presenting for outpatient intravenous prophylactic or on-demand replacement therapy using recombinant, pegylated antihemophilic factor (C9141). The clinical workflow begins with hematology assessment documenting factor VIII activity level and bleeding history. A prescription is written specifying dose in international units (I.U.) and frequency (e.g., prophylaxis every 3–5 days or episodic treatment for acute joint or soft-tissue bleeding). Prior to administration, nursing verifies patient identity, weight, allergy history, and venous access. Pharmacy prepares the appropriate vialed product and labels dose in I.U.; medication reconciliation and payer authorization are confirmed when required. Administration occurs in an outpatient infusion clinic, hemophilia treatment center, or home infusion setting by trained infusion nurses or supervised home infusion personnel. Post-infusion monitoring includes observation for infusion reactions, documentation of lot number and amount administered, and communication of any adverse events to the treating hematologist. Follow-up visits document clinical response, inhibitor testing as indicated, and adjustment of regimen for breakthrough bleeding or surgical procedures.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient |